TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 21.39%1.74B | -10.57%3.41B | 1.26%1.43B | -18.97%3.81B | -14.32%1.42B | 36.39%4.7B | 91.81%1.65B | 13.86%3.45B | --861.16M | 63.30%3.03B |
Operating income | 21.39%1.74B | -10.57%3.41B | 1.26%1.43B | -18.97%3.81B | -14.32%1.42B | 36.39%4.7B | 91.81%1.65B | 13.86%3.45B | 861.16M | 63.30%3.03B |
Cost of sales | -24.03%-972.96M | -50.45%-1.91B | -62.99%-784.45M | 10.99%-1.27B | -7.74%-481.3M | -40.29%-1.42B | -85.91%-446.74M | 22.44%-1.01B | ---240.3M | -62.09%-1.31B |
Operating expenses | -24.03%-972.96M | -50.45%-1.91B | -62.99%-784.45M | 10.99%-1.27B | -7.74%-481.3M | -40.29%-1.42B | -85.91%-446.74M | 22.44%-1.01B | -240.3M | -62.09%-1.31B |
Gross profit | 18.20%766.76M | -40.97%1.5B | -30.55%648.67M | -22.44%2.54B | -22.49%934.04M | 34.77%3.28B | 94.10%1.21B | 41.47%2.43B | 620.86M | 64.23%1.72B |
Selling expenses | 21.25%-329.16M | 9.11%-818.73M | -3.93%-417.96M | -32.16%-900.79M | -37.54%-402.15M | -27.04%-681.58M | -22.82%-292.39M | -18.38%-536.52M | ---238.07M | -121.42%-453.2M |
Administrative expenses | 7.73%-734.94M | 3.63%-1.51B | -3.63%-796.52M | 31.79%-1.57B | 46.74%-768.63M | -44.59%-2.3B | -39.09%-1.44B | -107.58%-1.59B | ---1.04B | -69.23%-765.72M |
Research and development expenses | -6.11%-1.89B | 13.67%-3.47B | 12.39%-1.78B | -11.07%-4.01B | -14.88%-2.04B | -47.28%-3.61B | -45.29%-1.77B | -28.08%-2.45B | ---1.22B | -125.71%-1.92B |
Impairment and provision | -48.21%-587.65M | -10.05%-1.84B | 26.87%-396.49M | -222.19%-1.67B | -203.49%-542.18M | 0.85%-517.61M | 21.36%-178.65M | -87.70%-522.05M | ---227.17M | -358.47%-278.12M |
-Other impairment is provision | -48.21%-587.65M | -10.05%-1.84B | 26.87%-396.49M | -222.19%-1.67B | -203.49%-542.18M | 0.85%-517.61M | 21.36%-178.65M | -87.70%-522.05M | ---227.17M | -358.47%-278.12M |
Special items of operating profit | 109.26%55.7M | 43.84%-516.74M | 0.60%-601.83M | -981.94%-920.06M | -283.46%-605.44M | -87.84%104.32M | 600.27%330.01M | 882.61%858.1M | ---65.97M | -51.77%87.33M |
Operating profit | 18.70%-2.72B | -1.81%-6.65B | 2.12%-3.35B | -75.03%-6.53B | -59.00%-3.42B | -105.86%-3.73B | 0.76%-2.15B | -12.78%-1.81B | -2.17B | -374.18%-1.61B |
Financing income | 107.31%350.15M | 31.25%341.98M | 37.89%168.9M | 38.80%260.55M | 26.79%122.49M | 7.33%187.72M | 0.10%96.61M | -34.75%174.9M | --96.51M | 154.51%268.06M |
Financing cost | -25.59%-85.86M | -164.55%-146.66M | -257.42%-68.37M | -64.22%-55.44M | 12.20%-19.13M | 70.00%-33.76M | 68.29%-21.79M | 24.93%-112.51M | ---68.71M | -408.25%-149.87M |
Special items of earning before tax | -19.46%-23.98M | -451.45%-52.92M | -236.27%-20.07M | 99.93%-9.6M | 99.65%-5.97M | -28.35%-13.57B | 48.65%-1.72B | -186.86%-10.57B | ---3.34B | -15.38%-3.68B |
Earning before tax | 24.05%-2.48B | -2.71%-6.5B | 1.67%-3.27B | 63.06%-6.33B | 12.41%-3.32B | -39.15%-17.14B | 30.83%-3.79B | -138.15%-12.32B | -5.48B | -49.67%-5.17B |
Tax | -96.79%3.99M | -96.04%9.49M | 8.67%124.22M | 775.44%239.82M | 42.82%114.3M | -122.10%-35.51M | -46.78%80.04M | -21.69%160.67M | --150.39M | 773.21%205.17M |
After-tax profit from continuing operations | 21.17%-2.48B | -6.59%-6.49B | 2.04%-3.14B | 64.53%-6.09B | 13.60%-3.21B | -41.28%-17.18B | 30.38%-3.71B | -144.75%-12.16B | -5.33B | -44.71%-4.97B |
Earning after tax | 21.17%-2.48B | -6.59%-6.49B | 2.04%-3.14B | 64.53%-6.09B | 13.60%-3.21B | -41.28%-17.18B | 30.38%-3.71B | -144.75%-12.16B | -5.33B | -44.71%-4.97B |
Minority profit | -2.77%-20.43M | -13.11%-54.51M | 60.50%-19.88M | -30.38%-48.19M | -389.45%-50.34M | -23,902.60%-36.96M | -14.04%-10.28M | 97.01%-154K | ---9.02M | -3.48%-5.14M |
Profit attributable to shareholders | 21.33%-2.46B | -6.54%-6.44B | 1.11%-3.12B | 64.73%-6.04B | 14.72%-3.16B | -40.98%-17.14B | 30.45%-3.7B | -145.00%-12.16B | -5.32B | -44.77%-4.96B |
Basic earnings per share | 20.00%-0.08 | -5.26%-0.2 | 0.00%-0.1 | 89.08%-0.19 | 74.36%-0.1 | -30.83%-1.74 | 35.00%-0.39 | -137.50%-1.33 | -0.6 | -43.59%-0.56 |
Diluted earnings per share | 20.00%-0.08 | -5.26%-0.2 | 0.00%-0.1 | 89.08%-0.19 | 74.36%-0.1 | -30.83%-1.74 | 35.00%-0.39 | -137.50%-1.33 | -0.6 | -43.59%-0.56 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.